Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries

Citation
S. Mauiyyedi et al., Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries, J AM S NEPH, 12(3), 2001, pp. 574-582
Citations number
43
Categorie Soggetti
Urology & Nephrology","da verificare
Journal title
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
ISSN journal
10466673 → ACNP
Volume
12
Issue
3
Year of publication
2001
Pages
574 - 582
Database
ISI
SICI code
1046-6673(200103)12:3<574:CHRIOA>2.0.ZU;2-3
Abstract
The pathogenesis of chronic renal allograft rejection (CR) remains obscure. The hypothesis that a subset of CR is mediated by antidonor antibody was t ested by determining whether C4d is deposited in peritubular capillaries (P TC) and whether it correlates with circulating antidonor antibodies. All ca ses (from January 1, 1990, to July 31, 1999) that met histologic criteria f or CR and had frozen tissue (28 biopsies, 10 nephrectomies) were included. Controls were renal allograft biopsies with chronic cyclosporine toxicity ( n = 21) or nonspecific interstitial fibrosis (n = 10), and native kidneys w ith end-stage renal disease (n = 10) or chronic interstitial fibrosis (n = 5). Frozen sections were stained by two-color immunofluorescence for C4d, t ype TV collagen and Ulex europaeus agglutinin I. Antidonor HLA antibody was sought by panel-reactive antibody analysis and/or donor cross matching in sera within 7 wk of biopsy. Overall, 23 of 38 CR cases (61%) had PTC staini ng for C4d, compared with 1 of 46 (2%) of controls (P < 0.001). C4d in PTC was localized at the interface of endothelium and basement membrane. Most o f the C4d-positive CR tested had antidonor HLA antibody (15 of 17; 88%); no ne of the C4d-negative CR tested (0 of 8) had antidonor antibody (P < 0.000 2). The histology of C4d-positive CR was similar to C4d-negative CR, and l- yr graft survival rates were 62% and 25%, respectively (P = 0.05). Since Au gust 1998, five of six C4d-positive CR cases have been treated with mycophe nolate mofetil +/- tacrolimus with a 100% 1-yr graft survival, versus 40% b efore August 1998 (P < 0.03). These data support the hypothesis that a subs tantial fraction of CR is mediated by antibody (immunologically active). C4 d can be used to separate this group of CR from the nonspecific category of chronic allograft nephropathy and may have the potential to guide successf ul therapeutic intervention.